Victor Gordo Gonzalez, MD
Internal Medicine · San Juan, PRNPI 1124113899
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 77.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $10,657 and has fallen 99.1% since, to $92 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $191.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$17K
- Merck$2K
- Penumbra, Inc.$1K
- AstraZeneca$477
- Sanofi-aventis U.S. LLC$474
- Boehringer Ingelheim$295
- plus $592 from 10 others
What the payments were for
- Consulting fees$5,70027%
- Speaking & faculty fees$10,30048%
- Travel & lodging$2,40711%
- Food & beverage$2,94614%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $16,551 |
| Merck | 7 | $1,714 |
| Penumbra, Inc. | 3 | $1,291 |
| AstraZeneca | 26 | $477 |
| Sanofi-aventis U.S. LLC | 15 | $474 |
| Boehringer Ingelheim | 9 | $295 |
| E.r. Squibb & Sons, L.L.C. | 5 | $225 |
| PBG Puerto Rico LLC | 5 | $95 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $62 |
| Amgen | 2 | $42 |
| Novo Nordisk | 2 | $38 |
| Mylan LLC | 2 | $31 |
| Medtronic | 2 | $30 |
| GSK | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Pfizer Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$10,586
- STEGLATRO$1,500
- Smart Coil$1,291
- SOTAGLIFLOZIN$200
- ELIQUIS$125
- JARDIANCE$100
How this compares
$21,394 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 569 | $647,503 |
| JardianceEmpagliflozin | 109 | $139,340 |
| EliquisApixaban | 127 | $137,149 |
| XareltoRivaroxaban | 102 | $111,038 |
| SynthroidLevothyroxine Sodium | 990 | $106,124 |
| JanumetSitagliptin Phos/Metformin Hcl | 92 | $85,114 |
| OzempicSemaglutide | 63 | $76,524 |
| TrulicityDulaglutide | 53 | $74,097 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 64 | $62,052 |
| JanuviaSitagliptin Phosphate | 44 | $56,024 |
| MounjaroTirzepatide | 24 | $40,067 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $32,205 |
| Xigduo XrDapaglifloz Propaned/Metformin | 34 | $28,965 |
| EntrestoSacubitril/Valsartan | 24 | $28,894 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 39 | $26,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $477 | $660,225589 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Glyxambi | $295 | $286,033260 claims |
| MerckJanumet, Januvia, Janumet Xr | $1,714 | $168,008175 claims |
| Johnson & JohnsonXarelto | $16,551 | $111,038102 claims |
| Novo NordiskOzempic | $38 | $76,52463 claims |
| Sanofi-aventis U.S. LLCLantus | $474 | $19,899107 claims |
| GSKTrelegy Ellipta | $26 | $15,22119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in San Juan
- Ricardo FernandezSan Juan$351K
- Norma SalgadoSan Juan$21K
- Roberto Calderon SantiagoSan Juan$20K
- Natalia Almodovar ArbeloSan Juan$9K
- Jeremy FelicianoSan Juan$8K
- Porfirio Diaz-RodriguezSan Juan$8K
- Pedro del Valle de TomasSan Juan$7K
- Rafael Figueroa NavarroSan Juan$6K
- Amilcar Torres FigueroaSan Juan$6K
- Hector Leon-FigueroaSan Juan$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.